Heather Johnson

Contributing Writer

All
Deals
Devices and Diagnostics
Digital
Genetics
Pharma

February 12 2020

Glaucoma 360: Promising data as the industry considers value

“Innovation remains the largest driver of healthcare cost increase,” said David Parke II, MD, American Academy of Ophthalmology CEO, during the Glaucoma Research Foundation’s (GRF) ...

March 19 2019

Will a New Drug Using Cannabinoids Achieve a Breakthrough for Glaucoma?

SAN FRANCISCO – Nemus Bioscience, a biopharmaceutical company based in Southern California, came to the Glaucoma 360 New Horizons Forum here in February to make ...

March 6 2019

How Glaucoma Device Companies Raise Funding to Navigate ‘Death Valley’

SAN FRANCISCO – At the Glaucoma 360 New Horizons Forum here, Emmett Cunningham, Jr., MD, PhD, moderating a panel on financing for emerging glaucoma device ...

February 20 2019

Parsing the Challenges of Reimbursement in the Glaucoma Space: Drug and Device Developers Address Elephant in the Room

SAN FRANCISCO – When it comes to securing reimbursement models, ophthalmic device and drug developers are facing mounting pressure. Payers are demanding more evidence on ...

February 5 2019

The State of the Art of Glaucoma Genetics

SAN FRANCISCO – Advances in glaucoma genetics potentially hold the key to new therapies for prevention, early detection, and a cure, researcher Janey L. Wiggs, ...